Literature DB >> 16528603

Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges.

Denise Avard1, Peter Bridge, Lucie M Bucci, Jocelyne Chiquette, Michel Dorval, Francine Durocher, Doug Easton, Béatrice Godard, David Goldgar, Bartha Maria Knoppers, Rachel Laframboise, Bernard Lespérance, Marie Plante, Sean V Tavtigian, Hélène Vézina, Brenda Wilson, Jacques Simard.   

Abstract

Today it is common to conduct research in collaboration with colleagues from different disciplines and institutions. The INterdisciplinary HEalth Research International Team on BReast CAncer susceptibility (INHERIT BRCAs), involves Canadian and international experts from diverse fields working with health service providers, patients and collaborators from the World Health Organization and other European networks. Evidence-based information and knowledge transfer drive our efforts to advance genomic research to understand the genetic basis of cancer susceptibility and treatment response. Several goals reveal the interdisciplinary team approach: (a) to estimate the prevalence and penetrance of BRCA1 and BRCA2 mutations and their deleterious impact upon different populations; (b) to pinpoint novel breast cancer susceptibility loci; (c) to assess the efficacy of clinical interventions; (d) to address changes in quality of life and health-related behaviour from the decision to undergo genetics testing and during follow-up; (e) to evaluate legal, social and ethical implications; and, finally; (f) to promote professional and public education by facilitating the transfer of research findings to clinical practice and informing policy makers. The lessons learned by the INHERIT research team and future challenges are presented.

Entities:  

Mesh:

Year:  2006        PMID: 16528603     DOI: 10.1007/s10689-005-2570-8

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  41 in total

1.  Support groups for people carrying a BRCA mutation.

Authors:  M Dorval; E Maunsell; M J Dugas; J Simard
Journal:  CMAJ       Date:  2001-09-18       Impact factor: 8.262

2.  Genetic testing for BRCA1 mutation in the UK.

Authors:  Diana M Eccles
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

3.  Increased power for case-control studies of single nucleotide polymorphisms through incorporation of family history and genetic constraints.

Authors:  Deborah Thompson; John S Witte; Martha Slattery; David Goldgar
Journal:  Genet Epidemiol       Date:  2004-11       Impact factor: 2.135

4.  Cancer prevention and the American Society of Clinical Oncology.

Authors:  Scott M Lippman; Bernard Levin; Dean E Brenner; Gary B Gordon; Carolyn R Aldige; Barnett S Kramer; Judy E Garber; Ernest Hawk; Patricia A Ganz; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2004-09-07       Impact factor: 44.544

5.  Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.

Authors:  Hélène Vézina; Francine Durocher; Martine Dumont; Louis Houde; Csilla Szabo; Martine Tranchant; Jocelyne Chiquette; Marie Plante; Rachel Laframboise; Jean Lépine; Heli Nevanlinna; Dominique Stoppa-Lyonnet; David Goldgar; Peter Bridge; Jacques Simard
Journal:  Hum Genet       Date:  2005-05-10       Impact factor: 4.132

6.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

7.  Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy.

Authors:  Isabelle Rouleau; Jocelyne Chiquette; Marie Plante; Jacques Simard; Michel Dorval
Journal:  J Obstet Gynaecol Can       Date:  2004-12

8.  Expanding the physician's duty of care: a duty to recontact?

Authors:  Martin Letendre; Béatrice Godard
Journal:  Med Law       Date:  2004

9.  Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.

Authors:  H F Vasen; N E Haites; D G Evans; C M Steel; P Møller; S Hodgson; D Eccles; P Morrison; D Stoppa Lyonet; J Chang-Claude; M Caligo
Journal:  Eur J Cancer       Date:  1998-11       Impact factor: 9.162

10.  Organizational challenges in clinical genomic research.

Authors:  Jill S Altshuler; David Altshuler
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

View more
  5 in total

1.  Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population.

Authors:  Michel Dorval; Karine Bouchard; Elizabeth Maunsell; Marie Plante; Jocelyne Chiquette; Stéphanie Camden; Michel J Dugas; Jacques Simard
Journal:  J Genet Couns       Date:  2008-05-15       Impact factor: 2.537

2.  Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.

Authors:  Jacques Simard; Martine Dumont; Anne-Marie Moisan; Valérie Gaborieau; Hélène Malouin; Francine Durocher; Jocelyne Chiquette; Marie Plante; Denise Avard; Paul Bessette; Claire Brousseau; Michel Dorval; Béatrice Godard; Louis Houde; Yann Joly; Marie-Andrée Lajoie; Gilles Leblanc; Jean Lépine; Bernard Lespérance; Hélène Vézina; Jillian Parboosingh; Roxane Pichette; Louise Provencher; Josée Rhéaume; Daniel Sinnett; Carolle Samson; Jean-Claude Simard; Martine Tranchant; Patricia Voyer; Douglas Easton; Sean V Tavtigian; Bartha-Maria Knoppers; Rachel Laframboise; Peter Bridge; David Goldgar
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

3.  Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer.

Authors:  Francine Durocher; Yvan Labrie; Geneviève Ouellette; Jacques Simard
Journal:  J Hum Genet       Date:  2007-10-18       Impact factor: 3.172

4.  BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Authors:  Antonis C Antoniou; Francine Durocher; Paula Smith; Jacques Simard; Douglas F Easton
Journal:  Breast Cancer Res       Date:  2005-12-12       Impact factor: 6.466

5.  Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.

Authors:  Francine Durocher; Yvan Labrie; Penny Soucy; Olga Sinilnikova; Damian Labuda; Paul Bessette; Jocelyne Chiquette; Rachel Laframboise; Jean Lépine; Bernard Lespérance; Geneviève Ouellette; Roxane Pichette; Marie Plante; Sean V Tavtigian; Jacques Simard
Journal:  BMC Cancer       Date:  2006-09-29       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.